CoChat

Cloaking nanoparticles with protein corona shield for targeted drug delivery.

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 8 of the 31 sources its claims cite were checked for support.

Abstract

Targeted drug delivery using nanoparticles can minimize the side effects of conventional pharmaceutical agents and enhance their efficacy. However, translating nanoparticle-based agents into clinical applications still remains a challenge due to the difficulty in regulating interactions on the interfaces between nanoparticles and biological systems. Here, we present a targeting strategy for nanoparticles incorporated with a supramolecularly pre-coated recombinant fusion protein in which HER2-binding affibody combines with glutathione-S-transferase. Once thermodynamically stabilized in preferred orientations on the nanoparticles, the adsorbed fusion proteins as a corona minimize interactions with serum proteins to prevent the clearance of nanoparticles by macrophages, while ensuring systematic targeting functions in vitro and in vivo. This study provides insight into the use of the supramolecularly built protein corona shield as a targeting agent through regulating the interfaces between nanoparticles and biological systems.

Overview

CoChat Summary

## TL;DR

This paper presents a mesoporous silica nanoparticle coated with a supramolecularly pre-oriented GST-fusion affibody “protein corona shield” (PCSN) that reduces serum protein adsorption while preserving receptor targeting. In HER2-positive SK-BR3 models, PCSN showed reduced macrophage uptake and improved tumor accumulation and camptothecin delivery compared with PEG-MSN.

## Key findings

  • PCSN construction was confirmed by multiple measures: surface charge shifted from about −40 mV for GSH-MSN to −5.3 mV for PCSN, hydrodynamic radius increased from about 140 ± 20 nm to 270 ± 20 nm, and the maximum loading of GST-HER2-Afb was 270 μg/mg.
  • Serum protein adsorption was much lower on PCSN: after 1 h in 55% FBS, adsorbed protein band intensity was reported as about 15-fold lower than on GSH-MSN; PCSN also showed no significant change in hydrodynamic radius or surface charge after serum exposure.
  • Proteomics identified 183 proteins on the particles; the 78 most abundant were analyzed, and PCSN had lower amounts of immune-response, complement, and coagulation proteins, with more apolipoproteins relative to GSH-MSN and PEG-MSN.
  • In vivo, PCSN improved delivery and efficacy in SK-BR3 xenografts: tumor fluorescence was 1.8-fold higher than PEG-MSN at 0.5 h, 2.5-fold higher at 48 h, and PCSN(CPT) produced about 90.0% inhibition of tumor growth and 2.5-fold enhancement of inhibitory effects versus PEG-MSN(CPT).

## Methods

  • The study built PCSN by supramolecularly attaching recombinant GST-HER2-Afb to glutathione-modified mesoporous silica nanoparticles; a randomized covalent version and a modified negative-control version were also prepared for comparison.
  • In vitro analyses used SK-BR3, MDA-MB468, HEK293T, and RAW264.7 cells, with serum-protein adsorption assessed by SDS-PAGE, LC-MS/MS proteomics, DLS/zeta/PDI, microscopy, flow cytometry, and viability assays.
  • In vivo work used female nude mice bearing SK-BR3 xenografts; biodistribution was tracked with DiD imaging and antitumor efficacy with camptothecin-loaded formulations given by intravenous injection.

## Limitations

  • The paper itself notes that its in vivo efficacy data come from a specific HER2-positive SK-BR3 xenograft model with 6 mice per group for imaging and treatment groups of 6 mice per group; broader generalizability is not directly shown.
  • The text makes evident that the work is largely a preclinical proof-of-concept study, so clinical safety and effectiveness in humans are not tested here (evident from the study design).
  • The paper discusses mechanistic interpretation of protein corona composition and apolipoprotein recruitment, but a fully causal molecular mechanism for targeting is not definitively established in the provided text (evident from the discussion).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-018-06979-4

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Protein corona shield nanoparticle (PCSN). a We introduce the protein corona shield (PCS) concept for an efficient target drug delivery system. Generally, nanoparticle drug carriers with a target ligand lose their targeting ability on being coated by blood proteins in a biological environment. However, the PCS system can inhibit blood protein adsorption to maintain the targeting ability and avoid unwanted clearance by the mononuclear phagocyte system. b Mass spectrometry analysis of the GST-HER2-Afb showed a mass of 36.3 kDa. c Zeta-potential analysis of mesoporous silica nanoparticle (MSN) (−23 mV), GSH-MSN (−39 mV), GST-HER2-Afb (−5.25 mV), and PCSN (−5.3 mV). d Size distribution plots of PCSN. e Images of cellular uptake of fluorescein 5 maleimide-modified GST-HER2-Afb by the target cell (SK-BR3) and the negative control (MCF-10A). f Transmission electron microscopic images of GSH-MSN and PCSN (scale bar represents 100 nm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)
Fig. 1 Protein corona shield nanoparticle (PCSN). a We introduce the protein corona shield (PCS) concept for an efficient target drug delivery system. Generally, nanoparticle drug carriers with a target ligand lose their targeting ability on being coated by blood proteins in a biological environment. However, the PCS system can inhibit blood protein adsorption to maintain the targeting ability and avoid unwanted clearance by the mononuclear phagocyte system. b Mass spectrometry analysis of the GST-HER2-Afb showed a mass of 36.3 kDa. c Zeta-potential analysis of mesoporous silica nanoparticle (MSN) (−23 mV), GSH-MSN (−39 mV), GST-HER2-Afb (−5.25 mV), and PCSN (−5.3 mV). d Size distribution plots of PCSN. e Images of cellular uptake of fluorescein 5 maleimide-modified GST-HER2-Afb by the target cell (SK-BR3) and the negative control (MCF-10A). f Transmission electron microscopic images of GSH-MSN and PCSN (scale bar represents 100 nm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)CC BY · PubMed Central
Fig. 2 Proteomic study of surface protein corona. a GSH-MSN, PEG-MSN, and PCSN were treated with 55% serum for 1, 2, and 4 h, and the amount of serum protein attached to the surface was determined by SDS-PAGE. b Band intensity difference. c Classification of protein corona components characterized by quantitative LC-MS/MS. A total of 183 proteins were identified and the 78 most abundant proteins were used to make the heat map. d Proteins attached to each particle were classified by weight (kDa), category, and pI. e GSH-MSN, PCSN(R), PCSN(−), and PCSN were treated with 55% serum for 1 h and the amount of serum protein attached to the surface was determined by SDS-PAGE. All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)
Fig. 2 Proteomic study of surface protein corona. a GSH-MSN, PEG-MSN, and PCSN were treated with 55% serum for 1, 2, and 4 h, and the amount of serum protein attached to the surface was determined by SDS-PAGE. b Band intensity difference. c Classification of protein corona components characterized by quantitative LC-MS/MS. A total of 183 proteins were identified and the 78 most abundant proteins were used to make the heat map. d Proteins attached to each particle were classified by weight (kDa), category, and pI. e GSH-MSN, PCSN(R), PCSN(−), and PCSN were treated with 55% serum for 1 h and the amount of serum protein attached to the surface was determined by SDS-PAGE. All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)CC BY · PubMed Central
Fig. 3 In vitro experiment and stealth effect of PCSN. a Schematic showing the avoidance of phagocytosis by a macrophage. b Confocal microscopy images of DiI-loaded PCSN and PEG-MSN, and free DiI incubated for 6 h in RAW264.7 cells (scale bar is 20 μm). c FACS analysis of PCSN and PEG-MSN incubated in RAW264.7 cells for 6 h. d Cell cytotoxicity assay of PCSN and free camptothecin (CPT) on RAW264.7 cells (48 h of incubation). e Schematic of the targeting ability of PCSN treated with 55% serum. Cellular uptake confocal microscopy images of f DiI-loaded PCSN to HEK293T cells (negative control) and to SK-BR3 (target cells). g Cellular uptake confocal microscopic images of camptothecin-loaded PCSN to SK-BR3 and cell cytotoxicity assay (scale bar is 10 μm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)
Fig. 3 In vitro experiment and stealth effect of PCSN. a Schematic showing the avoidance of phagocytosis by a macrophage. b Confocal microscopy images of DiI-loaded PCSN and PEG-MSN, and free DiI incubated for 6 h in RAW264.7 cells (scale bar is 20 μm). c FACS analysis of PCSN and PEG-MSN incubated in RAW264.7 cells for 6 h. d Cell cytotoxicity assay of PCSN and free camptothecin (CPT) on RAW264.7 cells (48 h of incubation). e Schematic of the targeting ability of PCSN treated with 55% serum. Cellular uptake confocal microscopy images of f DiI-loaded PCSN to HEK293T cells (negative control) and to SK-BR3 (target cells). g Cellular uptake confocal microscopic images of camptothecin-loaded PCSN to SK-BR3 and cell cytotoxicity assay (scale bar is 10 μm). All bar graphs were reported as means ± standard deviations (SDs) for three experimental replicates (n = 3)CC BY · PubMed Central
Fig. 4 Ex vivo and in vivo efficiency of PCSN. a, b Fluorescence images of organs and tumors 48 h after intravenous injection and biodistribution of injected formulations in animals with SK-BR3 tumor xenograft from fluorescence intensity analysis. In vivo antitumor effects in different treatment groups loaded with camptothecin (CPT) (1.5 mg/kg of mice) (scale bar is 2 cm). c Growth curve of tumor volume after intravenous injection with various groups of carriers until day 21 (n = 6 mice per group, mean ± 1 day [n = 6 mice per group, mean ± SD, statistical significance was calculated by one-way analysis of variance, *P < 0.05, **P < 0.01]
Fig. 4 Ex vivo and in vivo efficiency of PCSN. a, b Fluorescence images of organs and tumors 48 h after intravenous injection and biodistribution of injected formulations in animals with SK-BR3 tumor xenograft from fluorescence intensity analysis. In vivo antitumor effects in different treatment groups loaded with camptothecin (CPT) (1.5 mg/kg of mice) (scale bar is 2 cm). c Growth curve of tumor volume after intravenous injection with various groups of carriers until day 21 (n = 6 mice per group, mean ± 1 day [n = 6 mice per group, mean ± SD, statistical significance was calculated by one-way analysis of variance, *P < 0.05, **P < 0.01]CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 7 Not checked · 47 Own results and interpretations

26 more claims

Create a free account to see all 61 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 41 references

Cited by

See all 409

Metadata

Authors
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., Kim, C., Kang, S., & Ryu, J.-H.
Affiliations
Ulsan National Institute of Science and Technology (KR)
Corresponding author
  • Kim, Chaekyu
  • Kang, Sebyung
  • Ryu, Ja-Hyoung
Venue
Nature communications
Published
2018-10-31
Volume
9
Issue
1
Pages
4548-4548
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2898317973
Cited by
409
References
41
Citations by year
2026: 23 · 2025: 47 · 2024: 35 · 2023: 48 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 32 · 2018: 1
FWCI
14.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion, cc-by)
Funders
National Research Foundation of Korea (2015H1D3A1061983, 2018R1A6A1A03025810, 2016R1A5A1009405, 2017R1A2B4003617)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
protein corona, targeted drug delivery, nanoparticles, glutathione S-transferase, fusion protein, serum protein adsorption
MeSH terms
Protein Corona, RAW 264.7 Cells, Animals, Antineoplastic Agents, Blood Proteins, Female, Humans, Mice, Nude, Protein Binding, Drug Delivery Systems, Proteomics, Cell Line, Tumor, Mice, Nanoparticles, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cloaking nanoparticles with protein corona shield for targeted drug delivery. https://app.cochat.ai/papers/10.1038/s41467-018-06979-4
The paper
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., Kim, C., Kang, S., & Ryu, J.-H. (2018). Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nature communications. https://doi.org/10.1038/s41467-018-06979-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.